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0.05) on the SF 12. Properly monitored patients spent signiﬁ cantly more on total 
health care services (+$5243), outpatient visits (+$1023), and medications (+$1204), 
respectively (all P-values<0.05). CONCLUSIONS: In the US, nearly 40% patients with 
diabetes do not receive the proper diabetes monitoring controlling for racial and 
socioeconomic disparities. Anti-diabetics/insulin use, mental/cognitive status, physical 
health status, and health care expenditure may also interact with performing monitor-
ing. Barriers and cost-beneﬁ t for long-term monitoring should be studied.
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BACKGROUND: Advances in screening technology have led to rapid expansion of 
newborn screening as a public health initiative in the United States. Due to variation 
across states in program implementation, there is a lack of standardization and 
accountability, which can affect quality of care. Texas currently screens for 28 disor-
ders. OBJECTIVES: The Texas Newborn Screening Performance Measures Project 
was initiated with the objective of developing evidence-based performance measures 
to improve quality, accountability and uniformity in the care. METHODS: A three 
step approach was used for identiﬁ cation and development of key measures for seven most 
critical disorders: systematic reviews; impact assessment; and feasibility assessment. Impact 
assessments (likert scale) were based on National Quality Measures Clearinghouse™ 
(NQMC) criteria: scientiﬁ c soundness, relevance, health importance, impact on quality of 
care, and ability to address disparities in care. A likert scale was also used for feasibility 
assessment on key aspects: data availability, ease of collection, infrastructure and human 
resource needs, overall cost, and time constraints. RESULTS: A total of 50 performance 
measures were supported by scientiﬁ c evidence. Impact and feasibility assessments led 
to the approval of 33/50 measures. “Time to initiate treatment” received the highest 
scores on potential impact on patient outcomes (mean impact score 86.67/100, SD 
1.5). Other measures with potentially high impact (score >80/100) were: compliance 
with oral prophylactic medication and age at ﬁ rst Prevnar® vaccination in sickle cell 
disease; screening of at-risk family members in fatty acid disorders; frequency of 
growth assessments in congenital adrenal hyperplasia and phenylalanine levels in 
phenylketonuria. “Time to treatment” for individual disorders was also ranked very 
high on feasibility (mean feasibility score 88.67/100, SD 3.88). CONCLUSIONS: This 
is one of the ﬁ rst efforts to identify and develop evidence-based performance measures 
in newborn screening and can pave the way for system wide changes and development 
of national guidelines.
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OBJECTIVES: Investigate the type 2 diabetes mellitus (T2DM) treatment practice and 
achievement of therapeutic goals in a cohort of T2DM patients treated in the Brazilian 
PHCS. METHODS: This is a cross-sectional analysis of 383 T2DM outpatients 
treated in 5 cities covered by the PHCS. Data was collected using information from 
the previous year by interviewing patients using a validated questionnaire comple-
mented by medical chart review. Therapeutic goals suggested by the Brazilian Diabetes 
Society were used as standard treatment. RESULTS: Mean age was 60.5 ± 9.6 years, 
mean BMI 29.1 ± 5.3 Kg/m2 and mean duration of diabetes of 12.2 ± 8.75 years. The 
frequency of associated arterial hypertension was 66.8% (n = 256); obesity 39% n = 
144); dyslipidemia 69.6% (n = 267) and heart failure 5.5% (n = 21). Microvascular 
complications were present in 32.4% (n = 124); 8.1% (n = 31) had macrovascular 
complications; 18% (n = 69) had at least one micro and one macrovascular complica-
tion and 41.5% (n = 159) had no complications. Current treatment practice was: 3.6% 
(n = 14) diet only; 30% (n = 115) monotherapy with oral anti-diabetic (OAD); 37.8% 
(n = 145) combined therapy with more than one OAD agents; 23.2% (n = 89) com-
bined therapy with insulin and 5.2% (n = 20) just insulin. The most prescribed drug 
was metformin (41.4%), followed by insulin (19.1%), sulphonylureas (18.6%), DPP4 
inhibitors (8.7%), TZDs (5.5%), and others (6.7%). Medications for dyslipidemia 
was used by 47.5% (n = 178); cardiovascular drugs in 77.4% (n = 287) and anti-
obesity drugs in 4% (n = 15). Treatment targets were achieved in: 76.8% for systolic 
and diastolic blood pressure (<130 × 85 mmHg), 19.5% for BMI < 25 kg/m2, 28% 
for HDL cholesterol >55 women, 37.3% for HDL cholesterol >45 men and 28.2% 
reached the goal for HbA1c (within normal range). Only 6.8% of the group (n = 26) 
reached all the treatment targets. CONCLUSIONS: The national goals for glycemic 
control, blood pressure and lipid levels are rarely achieved in real-world clinical 
practice, even with the high use of medications. 
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OBJECTIVES: Diabetes mellitus type 2 (T2DM) is a chronically progressive disease 
and the treatment must be selected according to the pathophysiological phase of the 
disease at the time the treatment is begun. The Croatian public diabetology sector 
takes care of approximately 150,000 adults treated with oral hypoglycemic agents 
(OHA) alone or in combination with insulin. Our objective was assessment of the 
clinical and economic consequences of OHA treatment in T2DM from a Croatian 
health care system perspective. METHODS: The target population deﬁ ned for the 
study was diabetic patients treated with OHA alone. Medication consumption was 
quantiﬁ ed by using Pharmis and CroDiab data. a clinical expert panel provided 
resource-use information not available in published literature or health care databases. 
RESULTS: Current consumption data is showing that 62.8% patients are using OHA 
as monotherapy. Within this group, majority is using either biguanides or sulphonyl-
ureas. Patients treated with sulphonylureas are represented with almost the same 
percentage as those treated with biguanides (25% vs. 29%). Combination of two 
OHA is used in 34.2% while 3% of patients are treated by triple therapy. The most 
often choice in dual therapy is combination of biguanides and sulphonylureas while 
biguanides, sulphonylureas and thiazolidinediones in combination as the most favour-
able treatment option in triple therapy. Biguanides are used as a one of OHA in 61% 
of patients. CONCLUSIONS: Considering current clinical guidelines, lifetime beneﬁ ts 
of biguanides and facts that they are low-cost agent, relatively small proportion of 
T2DM patients are treated with this agent in Croatia. Findings of this investigation 
revealed real life pattern of T2DM treatment, which enables directing in better treating 
and more cost-effective management in Croatia.
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OBJECTIVES: Using a large, US administrative pharmacy claims database, calculate 
proportion of days covered (PDC) using actual days supply, and compare estimated 
PDC (ePDC) using days supply derived from drug-speciﬁ c Deﬁ ned Daily Dose (DDD) 
criteria. METHODS: Continuously eligible patients ﬁ lling non-insulin anti-diabetic 
medication were targeted from a large sample of pharmacy claims during 2008 and 
2009. Medications were grouped into ATC diabetes drug classes. Proportion of days 
covered (PDC) was calculated as the number of days a patient had medication in their 
possession divided by the number of days in the period. PDC was ﬁ rst calculated using 
actual days supply, then ePDC was calculated using an estimated days supply from 
DDD, strength, and pill quantity. The percent of patients adherent to therapy was 
deﬁ ned by a PDC > 0.80. The reliability of each method was assessed by Pearson 
correlation coefﬁ cients and agreement above chance was assessed using Kappa statis-
tics. RESULTS: Adherence was calculated for 163,750 patients taking non-insulin 
anti-diabetics. Overall, the PDC was 0.69 and ePDC 0.57. The two measures were 
also highly and signiﬁ cantly correlated (r = 0.73; P < 0.0001). The percent adherent 
was 48.8% (PDC) and 34.4% (ePDC), (Kappa = 0.50; P < 0.0001). At the medication 
class level, differences in PDC and ePDC ranged from 0.01 to 0.35, with correlation 
coefﬁ cients ranging from 0.40 to 0.93. Differences in the percent adherent metric 
ranged from −2.3 to 23.2, and kappa values from 0.22 to 0.89. CONCLUSIONS: 
Applying DDD estimates for the purposes of diabetes adherence estimation when 
lacking days supply values may provide reasonable estimates of adherence based on 
results presented here. At the medication class level there is greater variability in the 
reliability measures. Including claims from the U.S. only is a limitation of this analysis, 
as local treatment patterns may vary, and DDD values were not available for all U.S. 
medications.
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OBJECTIVES: Markov and Monte-Carlo (MC) models are often used to simulate 
Diabetes Mellitus (DM) and its complications over time, but reasons to choose the 
model type are poorly documented. a systematic literature review was performed to 
identify factors inﬂ uencing the choice of the model type. METHODS: Models simulat-
ing the progression of DM and its complications were selected from Medline and 
Embase databases. Literature reviews, methodological articles and non original models 
were excluded. Each full-paper selected went through a 31-item checklist via a double-
reading process. a qualitative analysis was performed to evaluate the accuracy of the 
model with the study question. RESULTS: Sixty-one models were selected, including 
